Athira Pharma
Athira Pharma develops novel small molecule therapies for diseases with limited treatment options, including metastatic breast cancer and ALS. Its lead drug candidates are lasofoxifene and brelgometon (ATH-1105), which are evaluated in clinical trials to improve care for patients through innovative research and product development.
Facts
- HQ
- Seattle
- Sectors
- Biopharmaceuticals, Biotech, Pharmaceuticals
- Employees
- 30
- Stage
- Series B
Is this your organization? Claim it
EIT Pharma, led by ex-Athira CEO Leen Kawas, raises $35M Series A to advance lonafarnib for chronic hepatitis D
Kirkland-based EIT Pharma, led by former Athira CEO Leen Kawas, raised $35 million in an oversubscribed Series A led by Propel Bio Partners to support FDA review, manufacturing and commercial preparations for lonafarnib as an oral treatment candidate for chronic hepatitis D. The FDA accepted EIT Pharma's New Drug Application for lonafarnib on Aug. 11; the drug was acquired from Eiger BioPharmaceuticals' 2024 bankruptcy sale.
Leen Kawas returns as CEO of Kirkland’s EIT Pharma after 2021 Athira exit, to advance lonafarnib
Leen Kawas has returned to operations as CEO of Kirkland-based EIT Pharma after leaving Athira in 2021 and running Propel Bio Partners with investor Richard Kayne; she will lead the small infectious-disease biotech as it advances its lead drug lonafarnib toward data readouts while balancing travel and investment work. The company has about a dozen employees, occupies a coworking space in Kirkland, and expects to need new Seattle-area office space within a year.
Athira Pharma raises $289M total, completes $204M IPO round in September 2020; backed by National Institute on Aging
Athira Pharma, a Seattle-based biotech, has raised $289M in disclosed funding with a $204M IPO round in September 2020 and is backed by the National Institute on Aging.
See all 40 news stories about Athira Pharma.
Seattle Flow is free for everyone.
- Claim and edit your profile
- Get alerts about you, your company, and anything else you care about
- Access the most comprehensive investor list in Seattle
- Join the conversation on news, podcasts, and events
People
-
Rachel Lenington Executive, Chief Operating Officer and Chief Development Officer